New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 13, 2012
06:33 EDTONCYOncolytics Biotech announce positive top line Reolysindata for Phase III study
Oncolytics Biotech announced initial positive top line data from the first endpoint in its double-blinded randomized Phase III clinical study examining REOLYSIN in combination with carboplatin and paclitaxel in second-line patients with platinum-refractory, taxane-naive head and neck cancers. The endpoint examines initial percentage tumour changes between the pre-treatment and first post-treatment scans, typically performed at six weeks post-first treatment, of all patients enrolled in the study. The analysis was designed to assess early differences in response between loco-regional tumours and metastatic tumours, as classified and observed by the investigators. This is the first, and to this point only, endpoint to be un-blinded for this study.
News For ONCY From The Last 14 Days
Check below for free stories on ONCY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 18, 2014
07:38 EDTONCYOncolytics Biotech price target lowered to $3 from $5 at RBC Capital
Subscribe for More Information
September 17, 2014
10:00 EDTONCYOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:10 EDTONCYOncolytics Biotech downgraded to Hold from Buy at Stifel
Stifel downgraded Oncolytics Biotech to Hold citing disappointing topline results from its Phase II pancreatic cancer study.
September 16, 2014
17:09 EDTONCYOncolytics Biotech announces patient data from phase 2 study with REOLYSIN
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use